Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 715-736 , December 2006

Monoclonal antibodies and immunoconjugates in acute myeloid leukemia

  • Sergio Amadori (Director)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +39 06 20903219; Fax: +39 06 20903221.

References 

  1. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood. 1983;62:124–132
  2. Simmons D, Seed B. Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells. Journal of Immunology (Baltimore, Md.: 1950). 1988;141:2797–2800
  3. Crocker PR. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell–cell interactions and signalling. Current Opinion in Structural Biology. 2002;12:609–615
  4. Ulyanova T, Blasioli J, Woodford-Thomas TA, et al. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. European Journal of Immunology. 1999;29:3440–3449
  5. Vitale C, Romagnani C, Puccetti A, et al. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proceedings of the National Academy of Sciences of the United States of America. 2001;98:5764–5769
  6. McGraw KJ, Rosenblum MG, Cheung L, et al. Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias. Cancer Immunology, Immunotherapy: CII. 1994;39:367–374
  7. van Der Velden VH, te Marvelde JG, Hoogeveen PG, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97:3197–3204
  8. Balaian L, Ball ED. Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells. Leukemia Research. 2001;25:1115–1125
  9. Balaian L, Zhong RK, Ball ED. The inhibitory effect of anti-CD33 monoclonal antibodies on AML cell growth correlates with Syk and/or ZAP-70 expression. Experimental Hematology. 2003;31:363–371
  10. Jilani I, Estey E, Huh Y, et al. Differences in CD33 intensity between various myeloid neoplasms. American Journal of Clinical Pathology. 2002;118:560–566
  11. Co MS, Avdalovic NM, Caron PC, et al. Chimeric and humanized antibodies with specificity for the CD33 antigen. Journal of Immunology (Baltimore, Md.: 1950). 1992;148:1149–1154
  12. Caron PC, Co MS, Bull MK, et al. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Research. 1992;52:6761–6767
  13. Caron PC, Jurcic JG, Scott AM, et al. A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood. 1994;83:1760–1768
  14. Caron PC, Dumont L, Scheinberg DA. Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 1998;4:1421–1428
  15. Feldman E, Kalaycio M, Weiner G, et al. Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2003;17:314–318
  16. Feldman EJ, Brandwein J, Stone R, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2005;23:4110–4116
  17. Jurcic JG, DeBlasio T, Dumont L, et al. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2000;6:372–380
  18. Jurcic JG. Antibody therapy for residual disease in acute myelogenous leukemia. Critical Reviews in Oncology/Hematology. 2001;38:37–45
  19. Soignet S, Fleischauer A, Polyak T, et al. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study. Cancer Chemotherapy and Pharmacology. 1997;40(supplement):S25–S29
  20. Hamann PR, Hinman LM, Hollander I, et al. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjugate Chemistry. 2002;13:47–58
  21. McGavin JK, Spencer CM. Gemtuzumab ozogamicin. Drugs. 2001;61:1317–1322[discussion 1323–1314]
  22. Hinman LM, Hamann PR, Wallace R, et al. Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Research. 1993;53:3336–3342
  23. Hiatt A, Merlock R, Mauch S, et al. Regulation of apoptosis in leukemic cells by analogs of dynemicin A. Bioorganic & Medicinal Chemistry. 1994;2:315–322
  24. Salzberg AA, Dedon PC. DNA bending is a determinant of calicheamicin target recognition. Biochemistry. 2000;39:7605–7612
  25. Kumar RA, Ikemoto N, Patel DJ. Solution structure of the calicheamicin gamma 1I-DNA complex. Journal of Molecular Biology. 1997;265:187–201
  26. Linenberger ML, Hong T, Flowers D, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98:988–994
  27. Jedema I, Barge RM, van der Velden VH, et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2004;18:316–325
  28. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2005;19:176–182
  29. Walter RB, Raden BW, Kamikura DM, et al. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood. 2005;105:1295–1302
  30. van der Velden VH, Boeckx N, Jedema I, et al. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2004;18:983–988
  31. Korth-Bradley JM, Dowell JA, King SP, et al. Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. Pharmacotherapy. 2001;21:1175–1180
  32. Dowell JA, Korth-Bradley J, Liu H, et al. Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. Journal of Clinical Pharmacology. 2001;41:1206–1214
  33. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood. 1999;93:3678–3684
  34. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2001;19:3244–3254
  35. Giles FJ, Cortes JE, Halliburton TA, et al. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. The Annals of Pharmacotherapy. 2003;37:1182–1185
  36. Larson RA, Boogaerts M, Estey E, et al. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2002;16:1627–1636
  37. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2001;7:1490–1496
  38. Roboz GJ, Knovich MA, Bayer RL, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leukemia & Lymphoma. 2002;43:1951–1955
  39. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002;99:4343–4349
  40. Amadori S, Suciu S, Stasi R, et al. Gemtuzumab ozogamicin (Mylotarg®) as single agent treatment for patients 61 years of age and older with acute myeloid leukemia who are not candidates for conventional chemotherapy: final results of AML-15B, a phase 2 study of the European Organisation for Research and Treatment of Cancer and Gruppo Italiano Malattie Ematologiche dell'Adulto (EORTC/GIMEMA) Leukemia Groups. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 2005;Aug 4 [Epub ahead of print]
  41. Cortes J, Tsimberidou AM, Alvarez R, et al. Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology. 2002;50:497–500
  42. Alvarado Y, Tsimberidou A, Kantarjian H, et al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. 2003;51:87–90
  43. Apostolidou E, Cortes J, Tsimberidou A, et al. Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leukemia Research. 2003;27:887–891
  44. Tsimberidou A, Cortes J, Thomas D, et al. Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leukemia Research. 2003;27:893–897
  45. Tsimberidou A, Estey E, Cortes J, et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003;97:1481–1487
  46. Tsimberidou AM, Estey E, Cortes JE, et al. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemotherapy and Pharmacology. 2003;52:449–452
  47. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003;102:4277–4283
  48. Amadori S, Suciu S, Willemze R, et al. Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica. 2004;89:950–956
  49. Paietta E. Expression of cell-surface antigens in acute promyelocytic leukaemia. Best Practice & Research Clinical Haematology. 2003;16:369–385
  50. Estey EH, Giles FJ, Beran M, et al. Experience with gemtuzumab ozogamycin (‘mylotarg’) and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood. 2002;99:4222–4224
  51. Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004;104:1995–1999
  52. Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood. 2003;101:3868–3871
  53. Reinhardt D, Diekamp S, Fleischhack G, et al. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie. 2004;27:269–272
  54. Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin (Mylotarg(R)) in pediatric patients with advanced CD33-positive acute myeloid leukemia. Blood. 2005;106:1183–1188
  55. Larson RA, Sievers EL, Stadtmauer EA, et al. A final analysis of the efficacy and safety of gemtuzumab ozogamicin in 277 patients with acute myeloid leukemia in first relapse. Blood. 2002;100:1312;(abstract)
  56. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003;102:1578–1582
  57. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92:406–413
  58. Bearman SI. Veno-occlusive disease of the liver. Current Opinion in Oncology. 2000;12:103–109
  59. Giles F, Estey E, O'Brien S. Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer. 2003;98:2095–2104
  60. Rajvanshi P, Shulman HM, Sievers EL, et al. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood. 2002;99:2310–2314
  61. McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clinical Lymphoma. 2002;2(supplement 1):S35–S39
  62. Giles F, Garcia-Manero G, Cortes J, et al. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica. 2002;87:1114–1116
  63. Versluys B, Bhattacharaya R, Steward C, et al. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood. 2004;103:1968
  64. Appelbaum FR, Matthews DC, Eary JF, et al. The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation. 1992;54:829–833
  65. Schwartz MA, Lovett DR, Redner A, et al. Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 1993;11:294–303
  66. Jurcic JG, Caron PC, Miller WH, et al. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 1995;9:244–248
  67. Burke JM, Caron PC, Papadopoulos EB, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplantation. 2003;32:549–556
  68. Sgouros G, Ballangrud AM, Jurcic JG, et al. Pharmacokinetics and dosimetry of an alpha-particle emitter labeled antibody: 213Bi-HuM195 (anti-CD33) in patients with leukemia. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine. 1999;40:1935–1946
  69. Jurcic JG, Larson SM, Sgouros G, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood. 2002;100:1233–1239
  70. Dahlke MH, Larsen SR, Rasko JE, et al. The biology of CD45 and its use as a therapeutic target. Leukemia & Lymphoma. 2004;45:229–236
  71. van der Jagt RH, Badger CC, Appelbaum FR, et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Research. 1992;52:89–94
  72. Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94:1237–1247
  73. Seitz U, Neumaier B, Glatting G, et al. Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia. European Journal of Nuclear Medicine. 1999;26:1265–1273
  74. Kotzerke J, Glatting G, Seitz U, et al. Radioimmunotherapy for the intensification of conditioning before stem cell transplantation: differences in dosimetry and biokinetics of 188Re- and 99mTc-labeled anti-NCA-95 MAbs. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine. 2000;41:531–537
  75. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood. 2001;98:565–572
  76. Klein SA, Hermann S, Dietrich JW, et al. Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium 188-labeled anti-CD66 monoclonal antibodies. Blood. 2002;99:2270–2271

PII: S1521-6926(06)00034-X

doi: 10.1016/j.beha.2006.05.001

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 715-736 , December 2006

Article Tools

* Image Usage & Resolution